Skip to main content
Kexing Biopharm logo

Kexing Biopharm — Investor Relations & Filings

Ticker · 688136 ISIN · CNE100006ZG6 LEI · 529900Z34Q1M9A907771 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2025-11-06 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688136

About Kexing Biopharm

https://www.kexingbiopharm.com/

Kexing Biopharm is an innovative biopharmaceutical enterprise engaged in the research, development, production, and sales of recombinant protein drugs and micro-ecological preparations. The company focuses on developing treatments for therapeutic areas including kidney diseases, oncology, antiviral therapy, autoimmune disorders, metabolic diseases, and degenerative diseases. A key product in its portfolio is Erythropoietin Injection. Kexing Biopharm maintains a comprehensive quality system that aligns with international standards, covering the entire drug lifecycle from production and quality control to release and transportation, ensuring the continuous and stable manufacturing of safe and effective medicines.

Recent filings

Filing Released Lang Actions
关于向香港联交所递交H股发行上市申请并刊发申请资料的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 科兴生物制药股份有限公司 regarding the submission of an application to the Hong Kong Stock Exchange for an H-share issuance and listing. It includes disclaimers about the application materials and provides links to the application documents on the HKEX website. The document is short (1041 characters) and primarily serves to inform investors about the filing and the availability of the application materials, rather than containing the full application or detailed financial data. It does not contain actual financial statements or substantive financial analysis. Therefore, it is an announcement related to capital raising and listing application, fitting the category of Capital/Financing Update (CAP).
2025-11-06 Chinese
关于以集中竞价交易方式回购公司股份的进展公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement from a company about the progress of its share repurchase program, detailing the number of shares repurchased, prices, and related board approvals. It references specific dates and regulatory compliance with stock exchange rules. The content focuses on the update of the company's share buyback activity rather than financial results or other report types. This fits the definition of a Transaction in Own Shares (POS) filing, which covers company buyback or sale of its own shares. The document length is short and it is not a report publication announcement or a certification. Therefore, the classification is POS with high confidence.
2025-11-03 Chinese
Kexing Biopharm prasentiert globale Strategie und Kooperationsmoglichkeiten auf der CPHI Frankfurt 2025
Regulatory Filings Classification · 100% confidence The document is a corporate press release issued via EQS News regarding Kexing Biopharm's participation in the CPHI Frankfurt 2025 trade fair. It discusses the company's global strategy, product portfolio, and international business development activities. As it does not fit into specific financial reporting categories like 10-K, ER, or IR, and is a general corporate announcement, it falls under the 'Regulatory Filings' (RNS) category as the fallback for miscellaneous corporate news.
2025-11-01 German
2025年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '科兴生物制药股份有限公司 2025 年第三季度报告', which translates to 'Sinovac Biotech Co., Ltd. 2025 Third Quarter Report'. It contains detailed financial data for the third quarter of 2025, including balance sheets, profit and loss statements, cash flow statements, and explanations of financial metrics and changes. The report explicitly states it is unaudited and covers the three-month period ending September 30, 2025. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year clearly identifies this as an Interim / Quarterly Report. The document length (over 14,000 characters) and detailed financial content confirm it is the report itself, not merely an announcement or certification. Therefore, the correct classification is 'IR' (Interim / Quarterly Report). 9M 2025
2025-10-29 Chinese
自愿披露关于GB18注射液I期临床试验完成首例受试者入组的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by a pharmaceutical company about the completion of the first subject enrollment in a Phase I clinical trial for a new drug (GB18 injection). It includes details about the drug, clinical trial approval, and progress, but does not contain financial statements, earnings data, or detailed financial analysis. It is an announcement of a clinical trial milestone rather than a financial report or regulatory filing related to financial performance. The document length is short (1489 characters) and it is an announcement of a clinical development event. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-10-29 Chinese
北京市嘉源律师事务所关于科兴生物制药股份有限公司2025年第二次临时股东会的法律意见书
Regulatory Filings
2025-10-17 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.